ChemoMetec Boosts Revenue and Profit Projections Significantly
ChemoMetec Enhances Revenue and Profit Guidance
ChemoMetec is pleased to announce a significant upgrade in its revenue and operating profit guidance, reflecting ongoing positive trends in its business operations. With the continued resilience in sales and a solid order intake, the company is set for an impressive financial performance.
Positive Market Performance
Throughout the recent quarter, ChemoMetec has experienced better-than-expected sales figures, which brings confidence to the management team. This upward trend can largely be attributed to the strengthening of the US dollar and a dedicated effort to optimize operating costs across the company.
Revised Financial Expectations
Given these encouraging developments, ChemoMetec now anticipates its revenue for the financial year 2024/25 to fall between DKK 470-490 million, marking a substantial increase from the previous guidance of DKK 460-475 million. Additionally, the company's EBITDA expectations have also been adjusted upward, now ranging from DKK 250-260 million, up from DKK 230-240 million.
Upcoming Financial Reports
Investors and stakeholders can look forward to the release of ChemoMetec's half-year financial report for the 2024/25 period, which is anticipated to be made public on a scheduled date in February.
Executive Contact Information
For further inquiries or detailed discussions, the following executives are available:
Martin Helbo Behrens, CEO
Contact Number: (+45) 48 13 10 20
Kim Nicolajsen, CFO
Contact Number: (+45) 48 13 10 20
About ChemoMetec A/S
ChemoMetec A/S specializes in the development, manufacturing, and marketing of innovative instruments used for cell counting and multiple forms of measurements. Their cutting-edge instruments serve a diverse clientele spread across the pharmaceutical, biotech, and agricultural sectors globally. ChemoMetec’s esteemed customers include some of the leading pharmaceutical entities in the world, demonstrating the company’s high standards of quality and reliability.
Company History and Presence
Founded in 1997, ChemoMetec has grown significantly and is now listed on Nasdaq OMX Copenhagen, reflecting its commitment to maintaining a robust presence in the global market.
Frequently Asked Questions
What is the new financial guidance for ChemoMetec for 2024/25?
The new revenue guidance is set between DKK 470-490 million, with EBITDA expectations ranging from DKK 250-260 million.
When will the half-year financial report be released?
ChemoMetec's half-year financial report is slated for release on a scheduled date in February 2025.
Who can be contacted for more information about ChemoMetec?
For inquiries, please contact Martin Helbo Behrens, CEO, or Kim Nicolajsen, CFO, both reachable at (+45) 48 13 10 20.
What industries does ChemoMetec serve?
ChemoMetec develops products for the pharmaceutical, biotech, and agricultural industries worldwide.
When was ChemoMetec founded?
ChemoMetec was established in 1997 and has since evolved into a key player in its field.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
